All In Biotech

Drug Trial Radar · NCT06603844

First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.

A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics and Efficacy of CRB-601, a Monoclonal Antibody Against Integrin avb8, in Patients With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

51

Actual

Start

Dec 4, 2024

Primary completion

Jan 30, 2026

Study completion Jan 30, 2026

Sponsor

Lead sponsor
Corbus Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Factorial
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the safety, blood concentrations and treatment effect of CRB-601 in combination with immunotherapy in patients who have advanced solid tumors (cancer) and have exhausted other therapeutic options.CRB-601 targets a protein called avb8 integrin which is expressed by some cancers and not others. This study will focus on tumor types which are know to highly or moderately express this protein. Researchers will evaluate the side effects caused by treatment, levels of CRB-601 in the blood, and the effect on the participant cancer. This will help researchers understand the right dose of CRB-601 to use for treatment and whether it is an effective treatment to combine with standard of care treatments such as immunotherapy. It will also help the researchers understand whether combining CRB-601 with standard-of-care immunotherapy and immune-priming radiotherapy is a safe and effective approach to treat cancer. Participants in the study will receive CRB-601 via an infusion every two weeks either alone or in combination with immunotherapy. There will be assessments to check on the participants general health status (including blood tests) and adverse effects. Participants will also receive regular CT or MRI scans to evaluate the effect of CRB-601 on their cancer. Participants will continue to visit the clinic every two weeks while they are receiving benefit from treatment. If their cancer progresses, participants will be asked to continue to be followed-up by the researchers to understand long-term outcomes, even if they receive other treatments.

Conditions

  • Solid Tumor

Interventions

  • CRB-601 monoclonal antibodyDrug

    CRB-601

  • Anti-PD-1 monoclonal antibodyDrug

    Anti-PD(L)-1 used as per label

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurance of Dose-limiting toxicitiesTime frame: 28 days
  2. Characterize the safety of CRB-601 in combination anti-PD(L)1 therapyTime frame: 6 months
  3. To evaluate the efficacy of CRB-601 in terms of DCR when administered in combination with anti-PD(L)-1Time frame: 6 months

Locations

26 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • SCRI - Arizona Oncology Associates

    Tucson, Arizona

  • The University of Arizona Cancer Center

    Tucson, Arizona

  • UC San Diego Health - Moores Cancer Center

    La Jolla, California

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • University of California San Francisco

    San Francisco, California

  • SCRI - Rocky Mountain Cancer Centers

    Denver, Colorado

  • Advent Health Oncology Hematology

    Orlando, Florida

  • SCRI- Lake Nona DDU

    Orlando, Florida

  • University of Chicago

    Chicago, Illinois

  • SCRI - Minnesota Oncology Hematology

    Maple Grove, Minnesota

  • Nebraska Hematology Oncology

    Lincoln, Nebraska

  • Duke Cancer Center

    Durham, North Carolina

  • University Hospital of Cleveland (Case Western)

    Cleveland, Ohio

  • SCRI - OU Health Stephenson Cancer Center

    Oklahoma City, Oklahoma

  • SCRI - Nashville

    Nashville, Tennessee

  • START - San Antonio

    San Antonio, Texas

  • SCRI- Texas Oncology

    Tyler, Texas

  • SCRI - Virginia Cancer Specialists

    Fairfax, Virginia

  • SCRI - Oncology and Hematology Associates of Southwest Virginia

    Roanoke, Virginia

  • Edinburgh Cancer Research Centre

    Edinburgh, United Kingdom

  • Beatson West of Scotland Cancer Center

    Glasgow, United Kingdom

  • Guys and St Thomas NHS Foundation Trust

    London, United Kingdom

  • The Newcastle upon Tyne Hospitals NHS Foundation Trust

    Newcastle upon Tyne, Tyne and Wear, United Kingdom

  • The Christie NHS Foundation Trust - Christie Hospital

    Manchester, United Kingdom, United Kingdom

  • The Clatterbridge Cancer Center NHS Foundation Trust

    Birkenhead, Wirral, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.